STOCK TITAN
  1. Home
  2. News
  3. IRME

IR-Med Inc - IRME STOCK NEWS

Welcome to our dedicated news page for IR-Med (Ticker: IRME), a resource for investors and traders seeking the latest updates and insights on IR-Med.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IR-Med's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IR-Med's position in the market.

News
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
Rhea-AI Summary
IR-MED Inc. achieves a significant milestone with the FDA listing of PressureSafe™ device for early detection of pressure injuries in the U.S. market. The device uses AI-driven spectrographic analysis technology to address healthcare needs, potentially revolutionizing patient care and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
none
-
News
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
Rhea-AI Summary
IR-MED Inc. reports highly favorable proof of efficacy data for PressureSafe™, a decision support device utilizing AI and infra-red spectroscopy to detect pressure injuries early. The study conducted at Clalit medical centers showed 92% sensitivity and 88% specificity in detecting early-stage pressure injuries, reducing pressure injuries incidence by 50%. The device is deemed safe, efficient, and valuable for early detection, especially in patients with darker skin tones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
News
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
Rhea-AI Summary
IR-MED Inc. announces final data from a study conducted at Clalit medical centers on PressureSafe, an AI-driven technology for pressure injury detection. The study results will be presented at the NPIAP 2024 Annual Conference, showcasing PressureSafe's efficacy in early-stage pressure injury detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences AI
News
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine
Rhea-AI Summary
IR-MED Inc. (OTCQB:IRME) has been awarded the 'Most Innovative Non-Invasive Diagnostics Technology Developer 2023 – Israel' by UK-based Corporate Vision Magazine for its PressureSafe™ device and technology platform. The non-invasive device is more than 90% accurate in detecting pressure injuries and is expected to launch in the U.S. in the first half of 2024, subject to regulatory approval. Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
Rhea-AI Summary
IR-MED Inc. (OTCQB:IRME) has been granted a patent for its PressureSafe™ decision support device, which offers more than 90% accuracy in the early detection of pressure injuries. The company's noninvasive AI-driven spectrographic analysis technology platform aims to address significant healthcare needs, with the U.S. healthcare burden from pressure injuries amounting to $26.8 billion annually. The patent, titled 'System and method for noninvasive analysis of tissue,' covers IR-MED's platform technology, a method for noninvasive analysis of subcutaneous tissue. This method uses infrared radiation (IR) to measure the intensity of the radiation in spectral bands emerging from the tissue, providing data-driven support for the diagnostic assessment of subcutaneous tissue. IR-MED's first product, PressureSafe™, is set to launch in the U.S. in the first half of 2024, offering a novel solution to the challenge of treating pressure injuries, particularly for people with darker skin tones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
News
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
Rhea-AI Summary
IR-MED Inc. announces Tzur Di-Cori as new CEO, bringing over 30 years of healthcare experience and expertise in building and executing business strategy. Commercial launch of PressureSafe™ in the U.S. expected in current fiscal quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
Rhea-AI Summary
IR-MED Inc. signs Clinical Trial Agreement with Methodist Healthcare System to conduct a usability study on PressureSafe device for early detection of pressure injuries. Interim results from a study in Israel show PressureSafe identified early-stage pressure injuries with 96% accuracy. Addressing healthcare equity for pressure injury detection is a priority for IR-MED. Pressure injuries cause 60,000 deaths annually in the US. Patient care cost per pressure injury ranges from $20,900 to $151,700. IR-MED's previous study showed PressureSafe detected pressure injuries with 96% sensitivity and 91% specificity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
Rhea-AI Summary
IR-MED Inc. appoints Richard Serbin, Esq. to its Advisory Board as the company prepares for regulatory listing of its PressureSafe™ device with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
Rhea-AI Summary
IR-MED plans to uplist its common stock to a major U.S. exchange. PressureSafe, expected to launch in H1 2024 pending FDA approval, addresses a $600 million market opportunity in the U.S. and $2.9 billion globally. Interim clinical data shows PressureSafe identifies early-stage pressure injuries with 96% accuracy. The company also plans to expand into Canada and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
AI
Stock IRME logo
IR-Med Inc

OTC:IRME

IRME Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IRME Stock Data

83.92M
22.00M
63.25%
Software Publishers
Information
Link
Israel
Rosh Pinna